Latest Breaking News On - Reference listed drug - Page 7 : vimarsana.com

Why Are Unicycive Therapeutics Shares Trading Lower Today - Unicycive Therapeutics (NASDAQ:UNCY)

Unicycive Therapeutics Inc (NASDAQ: UNCY) provided an update based on recent interactions with the FDA concerning the company's New Drug Application (NDA) for lanthanum dioxycarbonate (LDC), 

Unicycive Therapeutics (UNCY) Provides Regulatory Update on Lanthanum Dioxycarbonate Program

Unicycive Therapeutics Provides Regulatory Update on

LOS ALTOS, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Stock Market | FinancialContent Business Page

ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity

ANI Pharmaceuticals, Inc. today announced that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Applications for Methsuximide Capsules USP, 300 mg and... | May 15, 2023

ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP

ANI Pharmaceuticals, Inc. today announced that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Nitrofurantoin Oral Suspension USP, 25 mg/5... | June 18, 2023

Acasti Pharma (ACST) to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

ANI Pharmaceuticals Announces the FDA Approval of Colestipol Hydrochloride Tablets USP

ANI Pharmaceuticals, Inc. today announced that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Colestipol Hydrochloride Tablets USP, 1... | April 4, 2023

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Eisenmenger Complex Management Market to reach US$ 12.9 billion in 2033

The global Eisenmenger complex management market is expected to surpass an impressive valuation of US$ 7.7 billion in 2023 and is projected to reach US$ 12.9 billion by 2033, growing at a CAGR of 5.3%. Generally, the treatment includes relieving the symptoms and associated co-morbidities. Medications such as calcium...